Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs
Open accessAbstract
Tyrosine kinase inhibitors (TKIs) against the epidermal growth factor receptor (EGFR) are the standard of care treatment in non-small cell lung cancer (NSCLC). TKIs are used first line in EGFR mutation-positive NSCLC; erlotinib is the only TKI approved for subsequent lines of treatment in EGFR wild-type NSCLC. As promising as TKIs are in helping patients avoid some of the side effects of traditional cytotoxic chemotherapy, they do come with a variety of side effects. This article will describe the most common adverse events associated with the epidermal EGFR family of TKIs including diarrhea, rash, mucositis, and paronychia. The objective of this paper is to provide simple guidelines to assist oncologists in managing these common toxicities. As patient survival is often directly correlated with successful therapeutic drug delivery, the management of TKI-induced adverse events ensures proper treatment and may avoid discontinuation or reduction of the therapeutic.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Afatinib-related AEs are manageable by means of tolerability-guided dose adjustments, along with use of AE-specific treatment administered either prophylactically or as needed.
“afatinib-related AEs are manageable by means of tolerability-guided dose adjustments, along with the use of AE-specific treatment administered either prophylactically or as needed.”
From Afatinib for the treatment of <i>EGFR</i> mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · see citing works
Wu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J. H., Lee, K. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70604-1 · Cited by 1,978 · see citing works
Mechanisms of cutaneous toxicities to EGFR inhibitors
Lacouture, M. E. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1970 · Cited by 792 · see citing works
Blocking of EGF-Dependent Cell Proliferation by EGF Receptor Kinase Inhibitors
Yaish, P., Gazit, A., Gilon, C., & Levitzki, A. (1988) · Science · doi:10.1126/science.3263702 · Cited by 587 · see citing works
Lacouture, M. E., Anadkat, M. J., Bensadoun, R., Bryce, J., Chan, A., Epstein, J. B., Eaby‐Sandy, B., Murphy, B. A., & MASCC Skin Toxicity Study Group (2011) · Supportive Care in Cancer · doi:10.1007/s00520-011-1197-6 · Cited by 442 · see citing works
Yang, J. C., Hirsh, V., Schüler, M., Yamamoto, N., O'Byrne, K. J., Mok, T. S. K., Zazulina, V., Shahidi, M., Lungershausen, J., Dan Massey, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.1764 · Cited by 324 · see citing works
Self-citationMaroun, J. A., Anthony, L. B., Blais, N., Burkes, R. L., Dowden, S. D., Dranitsaris, G., Samson, B., Shah, A., Thirlwell, M. P., Vincent, M. D., et al. (2007) · Current Oncology · doi:10.3747/co.2007.96 · Cited by 162 · see citing works
Hirsh, V. (2011) · Current Oncology · doi:10.3747/co.v18i3.877 · Cited by 138 · see citing works
Self-citationClinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers
Harandi, A., Zaidi, A., Stocker, A. M., & Laber, D. A. (2009) · Journal of Oncology · doi:10.1155/2009/567486 · Cited by 114 · see citing works
Lacouture, M. E., & Lai, S. E. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07452.x · Cited by 98 · see citing works
Lacouture, M. E., & Melosky, B. (2007) · PubMed · Cited by 81 · see citing works
Self-citationUnderstanding and managing chemotherapy-induced diarrhea.
Saltz, L. B. (2003) · PubMed · Cited by 44 · see citing works
Supportive Care Treatments for Toxicities of Anti-EGFR and Other Targeted Agents
Melosky, B. L. (2012) · Current Oncology · doi:10.3747/co.19.1054 · Cited by 38 · see citing works
Self-citationIncreased Alpha-Fetoprotein Receptor in the Serum of Patients with Early-Stage Breast Cancer
Moro, R. D. P., Tcherkassova, J., & Stieber, P. (2012) · Current Oncology · doi:10.3747//co.19.979 · Cited by 21 · see citing works
Brown, C. G., & Yoder, L. H. (2002) · AJN American Journal of Nursing · doi:10.1097/00000446-200204001-00005 · Cited by 13 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Zhong, Q., Xiao, X., Qiu, Y., Xu, Z., Chen, C., Chong, B., Zhao, X., Hai, S., Li, S., An, Z., et al. (2023) · MedComm · doi:10.1002/mco2.261 · Cited by 442 · see citing works
The Ascension of Targeted Covalent Inhibitors
Singh, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02134 · Cited by 210 · see citing works
Zhou, C., Li, X., Wang, Q., Gao, G., Zhang, Y., Chen, J., Shu, Y., Hu, Y., Fan, Y., Fang, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00297 · Cited by 206 · see citing works
Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors
Vigarios, É., Epstein, J. B., & Sibaud, V. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3629-4 · Cited by 190 · see citing works
Eno, M. S., Brubaker, J. D., Campbell, J. E., Savi, C. D., Guzi, T. J., Williams, B. D., Wilson, D. P., Wilson, K. J., Brooijmans, N., Kim, J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00704 · Cited by 194 · see citing works
Herman, S. E. M., Montraveta, A., Niemann, C. U., Mora-Jensen, H. I., Gulrajani, M., Krantz, F., Mantel, R., Smith, L. L., McClanahan, F., Harrington, B. K., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0463 · Cited by 156 · see citing works
Solassol, I., Pinguet, F., & Quantin, X. (2019) · Biomolecules · doi:10.3390/biom9110668 · Cited by 123 · see citing works
Afatinib for the treatment of <i>EGFR</i> mutation-positive NSCLC: A review of clinical findings
Harvey, R. D., Adams, V. R., Beardslee, T., & Medina, P. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220931926 · Cited by 115 · see citing works
Shah, R. R., & Shah, D. R. (2019) · Drug Safety · doi:10.1007/s40264-018-0772-x · Cited by 99 · see citing works
Melosky, B. L., Anderson, H., Burkes, R. L., Chu, Q. S.-C., Hao, D., HO, V. C., Ho, C., Lam, W., Lee, C. W., Leighl, N. B., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3918 · Cited by 94 · see citing works
Self-citationHuang, J., Meng, L., Yang, B. L., Sun, S., Luo, Z., & Chen, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-61571-5 · Cited by 76 · see citing works
Tyrosine kinase inhibitors in breast cancer (Review)
Iancu, G., Şerban, D., Badiu, C. D., Tanasescu, C. A. H., TUDOSIE, M. D., Tudor, C., Costea, D. O., Zgura, A. F., Iancu, R. C., & Vasile, D. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.11037 · Cited by 68 · see citing works
Li, Y., Fu, R., Jiang, T., Duan, D., Wu, Y., Li, C., Li, Z., Ni, R., Li, L., & Liu, Y. Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.804212 · Cited by 65 · see citing works
Kato, T., Seto, T., Nishio, M., Goto, K., Yamamoto, N., Okamoto, I., Tao, L., Yu, W., Khaznadar, T., Tajima, K., et al. (2017) · Drug Safety · doi:10.1007/s40264-017-0596-0 · Cited by 58 · see citing works
Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
Chu, C., Choi, J. N., Eaby‐Sandy, B., Langer, C. J., & Lacouture, M. E. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0582 · Cited by 58 · see citing works
de Mello, R. A., Neves, N. M., Tadokoro, H., Amaral, G. A., Castelo‐Branco, P., & Zia, V. A. D. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113543 · Cited by 56 · see citing works
Jiao, L., Xu, J., Sun, J., Chen, Z., Gong, Y., Bi, L., Lu, Y., Yao, J., Zhu, W., Hou, A., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00732 · Cited by 51 · see citing works
Hofheinz, R., Segaert, S., Safont, M. J., Demonty, G., & Prenen, H. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.032 · Cited by 44 · see citing works
Pruritus Associated with Targeted Anticancer Therapies and Their Management
Wu, J., & Lacouture, M. E. (2018) · Dermatologic Clinics · doi:10.1016/j.det.2018.02.010 · Cited by 43 · see citing works
Hendriks, L. E. L., Schoenmaekers, J. J. A. O., Zindler, J. D., Eekers, D. B. P., Hoeben, A., Ruysscher, D. D., & Dingemans, A. C. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.05.005 · Cited by 41 · see citing works
Kujtan, L. A., & Subramanian, J. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1596030 · Cited by 40 · see citing works
Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma
Zhou, J. R., Wu, Z., Zhang, Z., Goss, L. B., McFarland, J. M., Nagaraja, A. K., Xie, Y., Gu, S. S., Peng, K., Zeng, Y., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-323276 · Cited by 38 · see citing works
Park, K., Lim, W., Okamoto, I., & Yang, J. C. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919836374 · Cited by 35 · see citing works
[EGFR-TKI ADR Management Chinese Expert Consensus].
(2019) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2019.02.01 · Cited by 36 · see citing works
Wu, J., Liu, D., Offin, M. D., Lezcano, C., Torrisi, J. M., Brownstein, S., Hyman, D. M., Gounder, M. M., Abida, W. M., Drilon, A. E. D. C., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-020-01035-9 · Cited by 33 · see citing works
Georgakopoulou, E. A., Stebbing, J., & Scully, C. M. (2018) · The Journal of the American Dental Association · doi:10.1016/j.adaj.2017.08.046 · Cited by 33 · see citing works
Kucharczuk, C., Ganetsky, A., & Vozniak, J. M. (2018) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2018.9.2.5 · Cited by 32 · see citing works
Ohe, Y., Kato, T., Sakai, F., Kusumoto, M., Endo, M., Saito, Y., Baba, T., Sata, M., Yamaguchi, O., Sakamoto, K., et al. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa067 · Cited by 30 · see citing works
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion
Stephens, D. M., & Spurgeon, S. E. F. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715592569 · Cited by 31 · see citing works
Lü, S., Shih, J., Jang, T. W., Liam, C. K., & Yu, Y. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01696-9 · Cited by 26 · see citing works
HyDRA: gene prioritization via hybrid distance-score rank aggregation
Kim, M., Farnoud, F., & Milenković, O. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu766 · Cited by 26 · see citing works
Yang, J. C., Mok, T. S. K., Han, B., Orlando, M., Puri, T., & Park, K. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.06.013 · Cited by 23 · see citing works
Edwards, R. L., Andan, C., Lalla, R. V., Lacouture, M. E., O’Brien, D., & Sequist, L. V. D. (2018) · Clinical journal of oncology nursing · doi:10.1188/18.cjon.542-548 · Cited by 22 · see citing works
Piotrowska, Z., Passaro, A., Nguyen, D., Ruiter, G., Soo, R. A., Lee, V. H.-F., Velcheti, V., Tan, D. S. W., Lee, S., Kim, S. H., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00763 · Cited by 20 · see citing works
Yasumuro, O., Uchida, S., Kashiwagura, Y., Suzuki, A., Tanaka, S., Inui, N., Watanabe, H., & Namiki, N. (2017) · Xenobiotica · doi:10.1080/00498254.2017.1396379 · Cited by 20 · see citing works
Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer
Zhou, J., Liu, S. M., & Wu, Y.-L. L. C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1753697 · Cited by 19 · see citing works
Mir, S. A., Muhammad, A., Padhiary, A., Ekka, N. J., Baitharu, I., Naik, P. K., & Nayak, B. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2171133 · Cited by 18 · see citing works
Liu, B., Gao, F., Zhao, H., Yuan, S., Peng, X., Zhang, P., Wang, J., Zhang, T., Duan, M., & Guo, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115590 · Cited by 18 · see citing works
Application of EGFR-TKIs in brain tumors, a breakthrough in future?
Feng, S., Liu, H., Yun, C., Zhu, W. Z., & Pan, Y. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06448-9 · Cited by 17 · see citing works
Borriello, A., Caldarelli, I., Bencivenga, D., Stampone, E., Perrotta, S., Oliva, A., & Ragione, F. D. (2016) · Oncotarget · doi:10.18632/oncotarget.12649 · Cited by 17 · see citing works
Annunziata, M. C., Ferrillo, M., Cinelli, E., Panariello, L., Rocco, D., & Fabbrocini, G. (2019) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2019.170 · Cited by 16 · see citing works
Management Strategies for Adverse Events Associated With EGFR TKIs in Non–Small Cell Lung Cancer
Vogel, W. H., & Jennifer, P. (2016) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2016.7.7.4 · Cited by 16 · see citing works
Hirsh, V., & Singh, J. R. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa197 · Cited by 15 · see citing works
Self-citationPistone, A., Durieux, V., Grigoriu, B. D., & Meert, A. (2018) · Journal of Intensive Care Medicine · doi:10.1177/0885066618787788 · Cited by 14 · see citing works
Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma
Cárdenas-Fernández, D., Pina, P. S., Turcott, J. G., Chávez-Tapia, N. C., Conde‐Flores, E., Cardona, A. F., & Arrieta, O. G. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231192396 · Cited by 13 · see citing works
de Mello, R. A., Escriu, C., Castelo‐Branco, P., Cabral, P. L., Mountzios, G., Lopes, G. D. L., Jr., & Madureira, P. (2017) · Oncotarget · doi:10.18632/oncotarget.23668 · Cited by 9 · see citing works
Milgram, B. C., Borrelli, D. R., Brooijmans, N., Henderson, J. A., Hilbert, B. J., Huff, M. R., Ito, T., Jackson, E. L., Jonsson, P., Ladd, B., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02377 · Cited by 8 · see citing works
Masago, K., Imamichi, F., Masuda, Y., Ariga, N., Fujitomi, K., Fukumine, Y., Hatakenaka, K., Fujita, S., & Katakami, N. (2018) · Asia-Pacific Journal of Oncology Nursing · doi:10.4103/apjon.apjon_33_18 · Cited by 8 · see citing works
D’Souza, P. C., & Kumar, S. (2017) · Asia-Pacific Journal of Oncology Nursing · doi:10.4103/apjon.apjon_28_17 · Cited by 7 · see citing works
Liu, H., Chuang, C., Chen, C.-L., Wei, P., & Yang, C. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221122051 · Cited by 6 · see citing works
Personalized medicine for non-small cell lung cancer: where are we now and where can we go?
Ezeife, D. A., & Leighl, N. B. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2018.1411805 · Cited by 6 · see citing works
Yang, Y., Sang, J., Peng, L., Zeng, D., Jiang, H., Jiang, H., Chen, Z., Zou, R., Tang, J., Huang, X., et al. (2025) · Journal of Functional Foods · doi:10.1016/j.jff.2025.106968 · Cited by 5 · see citing works
Lung cancer in never smokers: from early detection to prevention
Caswell, D. R., Hiley, C. T., Murphy, C., Bao, L. C., & Swanton, C. (2026) · Trends in cancer · doi:10.1016/j.trecan.2025.12.009 · Cited by 5 · see citing works
He, P., Li, H., Yang, Z., Zhang, R., Ye, Q., Ta, D., Li, W., He, S., Dong, G., Zhou, Y., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117323 · Cited by 4 · see citing works
Turcott, J. G., Cárdenas-Fernández, D., Sánchez-Lara, K., Palomares-Palomares, C. B., & Arrieta, O. G. (2025) · Nutrition and Cancer · doi:10.1080/01635581.2025.2478649 · Cited by 4 · see citing works
Tu, H., & Wu, Y.-L. L. C. (2020) · Future Oncology · doi:10.2217/fon-2020-0320 · Cited by 4 · see citing works
Wang, Y., Zhang, G., Zhou, Z., Zhang, N., Jiang, H., Liu, Y., Fu, T., Zhu, Y., & Li, J. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202402884 · Cited by 3 · see citing works
Sun, Y., Wei, L.-M., & Qian, Y. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2506302 · Cited by 3 · see citing works
Summers, Y., & Graham, D. M. (2019) · European Journal of Oncology Pharmacy · doi:10.1097/op9.0000000000000018 · Cited by 3 · see citing works
Wang, K., Li, J., Sun, J., Li, L., Zhang, X., Zhang, J., Yu, M., Ye, X., Zhang, M., Zhang, Y., et al. (2021) · PubMed Central · doi:10.3779/j.issn.1009-3419.2021.102.32 · Cited by 3 · see citing works
Zhang, J., Lu, X., Zhang, X., Tan, K., Li, J., & Cui, H. (2022) · Integrative Cancer Therapies · doi:10.1177/15347354221140409 · Cited by 2 · see citing works
Gulikers, J. L., Bruinsma, J., Schoenmaekers, J. J. A. O., Dursun, S., Tjan‐Heijnen, V. C. G., van Geel, R. M. J. M., Croes, S., & Hendriks, L. E. L. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241303403 · Cited by 2 · see citing works
The Treatment of Metastatic Non-Small Cell Lung Cancer in a New Era of Personalized Medicine
Hirsh, V. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00020 · Cited by 2 · see citing works
Self-citationSafety and efficacy of targeted agents monotherapy in advanced NSCLC
Zhang, Q., & Wu, Y.-L. L. C. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1101340 · Cited by 1 · see citing works
Otorhinolaryngological Toxicities of New Drugs in Oncology
Hartl, D. M., Morel, D., Saavedra, E., Massard, C., Rinaldo, A., Saba, N. F., Ferlito, A., & Soria, J. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0512-0 · Cited by 1 · see citing works
Towards Manageable Toxicities From Targeted Lung Cancer Treatment
Mohindra, N. A., & Patel, J. D. (2015) · Lung Cancer Management · doi:10.2217/lmt.15.30
Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
Marcoux, N., & Sequist, L. V. D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55433-6.00007-9
Nursing Considerations for Patients Treated with Targeted Therapies
Goodwin, K. E., & Davies, M. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-16550-5_9
Pannoi, T., Sunphakorn, C., Detkaew, N., Chernghom, P., Nimor, K., Tongsai, P., Suknukul, P., Biswas, M., & Majam, T. (2025) · Research Square · doi:10.21203/rs.3.rs-8138030/v1
Gan, H. K., Parakh, S., Ameratunga, M., Hamid, A., Iatropoulos, G., Beecher, M., Cao, D., Westcott, K. T., Caine, J., Palmer, J., et al. (2026) · Cancers · doi:10.3390/cancers18203313
BindingDB Entry 50016732: The Ascension of Targeted Covalent Inhibitors.
BindingDB (2023) · UC San Diego · doi:10.7270/q23f4tpf
- Authors
- Melosky, B., & Hirsh, V.
- Affiliations
- BC Cancer Agency (CA)
- Royal Victoria Regional Health Centre (CA)
- Corresponding author
- Melosky, Barbara
- ORCID
- Melosky, Barbara
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2014-09-16
- Volume
- 4
- Pages
- 238-238
- ISSN
- 2234-943X (ISSN-L)
- PMC
- PMC4165207
- OpenAlex
- W1984047229
- Cited by
- 73
- References
- 16
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 5 · 2020: 8 · 2019: 9 · 2018: 8 · 2017: 9 · 2016: 3 · 2015: 6 · 2014: 1
- FWCI
- 5.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Frontiers in Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
- Keywords
- EGFR tyrosine kinase inhibitors, non-small cell lung cancer, metastatic non-small cell lung cancer, drug toxicity management, diarrhea, rash, mucositis, paronychia, erlotinib
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
